4157 On Other Exchanges
Symbol
Exchange
Taiwan

taigen biopharmaceuticals (4157) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAIGEN BIOPHARMACEUTICALS (4157)
\

Related News

No related news articles were found.

taigen biopharmaceuticals (4157) Related Businessweek News

No Related Businessweek News Found

taigen biopharmaceuticals (4157) Details

TaiGen Biopharmaceuticals Holdings Limited, through its subsidiary, TaiGen Biotechnology Co., Ltd., engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes-related complications in Taiwan and internationally. Its product portfolio includes Taigexyn (Nemonoxacin), a novel non-fluorinated quinolone antibacterial drug for the treatment of bacterial infections. The company’s development projects comprise Nemonoxacin for treating community-acquired pneumonia and diabetic foot infection; Burixafor (TG-0054), a CXCR4 chemokine receptor antagonist for stem cell transplantation and hematological cancer chemosensitization, as well as for treating myocardial infarction; and Furaprevir (TG-2349), a novel inhibitor of Hepatitis C virus NS3/4A protease. TaiGen Biopharmaceuticals Holdings Limited was founded in 2001 and is based in Taipei, Taiwan.

Founded in 2001

taigen biopharmaceuticals (4157) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

taigen biopharmaceuticals
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2019

TaiGen Biopharmaceuticals Holdings Limited announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced net loss was TWD 54.079 million compared to TWD 25.462 million a year ago. Basic loss per share was TWD 0.08 compared to TWD 0.04 a year ago.

Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2018

Taigen Biopharmaceuticals Holdings Limited announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was TWD 29.618 million compared to TWD 553.208 million a year ago. Operating loss was TWD 258.397 million compared to operating Income of TWD 260.425 million a year ago. Net loss was TWD 343.210 million compared to net income of TWD 746.378 million a year ago. Basic loss per share was TWD 0.48 compared to basic earnings per share of TWD 1.04 a year ago. Diluted eps was TWD 0 compared to TWD 1.04 a year ago.

Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter Ended September 30, 2018

Taigen Biopharmaceuticals Holdings Limited announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced sales was TWD 4.954 million compared to TWD 8.140 million a year ago. Operating loss was TWD 66.743 million compared to TWD 69.341 million a year ago. Net loss was TWD 124.573 million compared to TWD 43.718 million a year ago. Basic loss per share was TWD 0.17 compared to TWD 0.06 a year ago. Diluted eps was TWD 0 compared to diluted loss per share of TWD 0.06 a year ago. For the nine months, sales was TWD 24.932 million compared to TWD 550.584 million a year ago. Operating loss was TWD 174.330 million compared to operating Income of TWD 332.978 million a year ago. Net loss was TWD 247.460 million compared to net income of TWD 877.233 million a year ago. Basic loss per share was TWD 0.35 compared to basic earnings per share of TWD 1.22 a year ago. Diluted eps was TWD 0 compared to TWD 1.22 a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4157 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4157.
View Industry Companies
 

Industry Analysis

4157

Industry Average

Valuation 4157 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 613.6x
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 601.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAIGEN BIOPHARMACEUTICALS, please visit www.taigenbiotech.com.tw. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.